Pub Date : 2022-12-22DOI: 10.20471/lo.2022.50.02-03.09
Dragan Marinić Korolija, I. Kirac, L. Mayer, S. Varga
Background: Gender equality policy has been instituted in institutions across the European Union and the United States. Based on landscapes drawn over a decade ago about gender inequalities in health management. Oncology is projected to be a significant burden for healthcare systems very soon. Aim: to record leadership gender status in most prominent oncology institutions in 2022. Materials and methods: We searched the Organisation of European Cancer Institute website and the National Cancer Center Network Member Institutions website. We recorded the gender of the legal representative of the center (CEO/director). Results: The Organisation of the European Cancer Institute has a membership of 123 cancer centers, seven outside the European Union. Those situated in the EU have 17 leaders of the female sex (out of 116; 14,66%). While in the US, there are seven leaders of the female gender (out of 32; 21,88%). Conclusion: The introduction of gender equality policy in recent years slowly impacts the predominance of the male gender in leading positions of oncology centers.
{"title":"Gender equality in leading cancer centers","authors":"Dragan Marinić Korolija, I. Kirac, L. Mayer, S. Varga","doi":"10.20471/lo.2022.50.02-03.09","DOIUrl":"https://doi.org/10.20471/lo.2022.50.02-03.09","url":null,"abstract":"Background: Gender equality policy has been instituted in institutions across the European Union and the United States. Based on landscapes drawn over a decade ago about gender inequalities in health management. Oncology is projected to be a significant burden for healthcare systems very soon. Aim: to record leadership gender status in most prominent oncology institutions in 2022. Materials and methods: We searched the Organisation of European Cancer Institute website and the National Cancer Center Network Member Institutions website. We recorded the gender of the legal representative of the center (CEO/director). Results: The Organisation of the European Cancer Institute has a membership of 123 cancer centers, seven outside the European Union. Those situated in the EU have 17 leaders of the female sex (out of 116; 14,66%). While in the US, there are seven leaders of the female gender (out of 32; 21,88%). Conclusion: The introduction of gender equality policy in recent years slowly impacts the predominance of the male gender in leading positions of oncology centers.","PeriodicalId":53700,"journal":{"name":"Libri Oncologici","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42095422","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-12-22DOI: 10.20471/lo.2022.50.02-03.16
Sara Bilić-Knežević, Mirisa Tokić, T. Gulic, M. Avirović, D. Grebić
Metallothioneins (MTs) are a family of small cysteine-rich proteins involved in many physiological and pathological processes. Genes that encode the four isoforms of metallothioneins (MT1-M4) are located on chromosome 16q13. Strucutures of these four isoforms allow metallothioneins their various biological functions. Many studies have shown that MT plays an important role in carcinogenesis, tumour growth, its progression from local to metastatic disease and may contribute to resistence to chemotherapy and radiotherapy. Due to the fact that breast cancer is one of the leading causes of death in women worldwide it is important to better understand the biology of breast cancer. So, findings of MT could evenutally help as a prognostic tool and could lead to a possible new specific anti-cancer treatment.
{"title":"The role of metallothionein in breast cancer","authors":"Sara Bilić-Knežević, Mirisa Tokić, T. Gulic, M. Avirović, D. Grebić","doi":"10.20471/lo.2022.50.02-03.16","DOIUrl":"https://doi.org/10.20471/lo.2022.50.02-03.16","url":null,"abstract":"Metallothioneins (MTs) are a family of small cysteine-rich proteins involved in many physiological and pathological processes. Genes that encode the four isoforms of metallothioneins (MT1-M4) are located on chromosome 16q13. Strucutures of these four isoforms allow metallothioneins their various biological functions. Many studies have shown that MT plays an important role in carcinogenesis, tumour growth, its progression from local to metastatic disease and may contribute to resistence to chemotherapy and radiotherapy. Due to the fact that breast cancer is one of the leading causes of death in women worldwide it is important to better understand the biology of breast cancer. So, findings of MT could evenutally help as a prognostic tool and could lead to a possible new specific anti-cancer treatment.","PeriodicalId":53700,"journal":{"name":"Libri Oncologici","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43836874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-12-22DOI: 10.20471/lo.2022.50.02-03.20
Z. Rendić-Miočević, M. Alvir, I. Orešković, L. Beketić-Orešković
The aim of this review article is to present current options for fertility preservation in young women with gynecological tumors (ovarian, endometrial or cervical cancer). An early pretreatment referral to multidisciplinary team which consists of general gynecologists, gynecologic oncologists, embryologists, radiologists, pathologists, and reproductive endocrinologists should be suggested to young women with gynecologic cancer, concerning the risks and benefits of fertility preservation options. Only a small percentage of patients with ovarian cancer and borderline ovarian tumors, are appropriate candidates for fertility preservation (FIGO stage IA and IC epithelial ovarian cancer). Following oophorectomy, ovarian tissue or oocytes are removed from the ovary for the use of cryopreservation; after completion of oncological treatment patient undergoes orthotopic retransplantation of ovarian tissue whereas oocytes may be used for in vitro fertilization. Live birth rates up to 53.8% have been reported after fertility preservation treatment in selected patients. In patients with endometrial cancer fertility preservation treatment means conserving of the uterus. Appropriate candidates for fertility preservation are younger women with well differentiated endometrial cancer, which does not invade the myometrium. Fertility preservation treatment in endometrial cancer is hormonal, based on progestins. After completion of fertility preservation treatment, frequent follow-ups are necessary, with tissue sampling (via curettage or endometrial biopsy) remaining standard approach in follow- up. Live birth rates after progestin therapy are around 60%, or even higher with the help of assisted reproductive procedures. In cervical cancer, fertility preservation treatment can be considered in women with early-stage disease (FIGO IA1, IA2, or IB1). Cone biopsy or conization followed by laparoscopic lymphadenectomy has been described as an appropriate procedure, with conception rates up to 47%.
{"title":"Fertility preservation in patients with gynecological cancer - is it possible?","authors":"Z. Rendić-Miočević, M. Alvir, I. Orešković, L. Beketić-Orešković","doi":"10.20471/lo.2022.50.02-03.20","DOIUrl":"https://doi.org/10.20471/lo.2022.50.02-03.20","url":null,"abstract":"The aim of this review article is to present current options for fertility preservation in young women with gynecological tumors (ovarian, endometrial or cervical cancer). An early pretreatment referral to multidisciplinary team which consists of general gynecologists, gynecologic oncologists, embryologists, radiologists, pathologists, and reproductive endocrinologists should be suggested to young women with gynecologic cancer, concerning the risks and benefits of fertility preservation options. Only a small percentage of patients with ovarian cancer and borderline ovarian tumors, are appropriate candidates for fertility preservation (FIGO stage IA and IC epithelial ovarian cancer). Following oophorectomy, ovarian tissue or oocytes are removed from the ovary for the use of cryopreservation; after completion of oncological treatment patient undergoes orthotopic retransplantation of ovarian tissue whereas oocytes may be used for in vitro fertilization. Live birth rates up to 53.8% have been reported after fertility preservation treatment in selected patients. In patients with endometrial cancer fertility preservation treatment means conserving of the uterus. Appropriate candidates for fertility preservation are younger women with well differentiated endometrial cancer, which does not invade the myometrium. Fertility preservation treatment in endometrial cancer is hormonal, based on progestins. After completion of fertility preservation treatment, frequent follow-ups are necessary, with tissue sampling (via curettage or endometrial biopsy) remaining standard approach in follow- up. Live birth rates after progestin therapy are around 60%, or even higher with the help of assisted reproductive procedures. In cervical cancer, fertility preservation treatment can be considered in women with early-stage disease (FIGO IA1, IA2, or IB1). Cone biopsy or conization followed by laparoscopic lymphadenectomy has been described as an appropriate procedure, with conception rates up to 47%.","PeriodicalId":53700,"journal":{"name":"Libri Oncologici","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48461395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-12-22DOI: 10.20471/lo.2022.50.02-03.14
G. Vuletić
For many years, cancer have been the 2nd leading cause of death, both men and women, in Croatia, and breast cancer is among first three cause of death from cancer in women. Disease, especially cancer, has negative and multidimensional impact on quality of life. The aim of this research was to examine the relation between perceived social support and body image with quality of life in women with breast cancer who undergone surgical treatment mastectomy. Results showed that quality of life after the mastectomy in women with breast cancer was 53.58 %SM which was below the normative range, and indicating decreased QoL. Social support proves to be strongest protective factor for the quality of life in women with breast cancer who undergone mastectomy, and longer time from diagnosis was also associated with higher quality of life. Neither women’s age, level of body image disturbance nor type of additional treatment were shown to be significant predictors of the overall QoL Assessment of quality of life and perceived social support could become a valuable indicator of the success of multidisciplinary treatment and indicate areas where the woman needs additional help and support in order to achieve better quality of life.
{"title":"Quality of life in relation to social support and body image in women with breast cancer after mastectomy","authors":"G. Vuletić","doi":"10.20471/lo.2022.50.02-03.14","DOIUrl":"https://doi.org/10.20471/lo.2022.50.02-03.14","url":null,"abstract":"For many years, cancer have been the 2nd leading cause of death, both men and women, in Croatia, and breast cancer is among first three cause of death from cancer in women. Disease, especially cancer, has negative and multidimensional impact on quality of life. The aim of this research was to examine the relation between perceived social support and body image with quality of life in women with breast cancer who undergone surgical treatment mastectomy. Results showed that quality of life after the mastectomy in women with breast cancer was 53.58 %SM which was below the normative range, and indicating decreased QoL. Social support proves to be strongest protective factor for the quality of life in women with breast cancer who undergone mastectomy, and longer time from diagnosis was also associated with higher quality of life. Neither women’s age, level of body image disturbance nor type of additional treatment were shown to be significant predictors of the overall QoL Assessment of quality of life and perceived social support could become a valuable indicator of the success of multidisciplinary treatment and indicate areas where the woman needs additional help and support in order to achieve better quality of life.","PeriodicalId":53700,"journal":{"name":"Libri Oncologici","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46565159","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-12-22DOI: 10.20471/lo.2022.50.02-03.11
M. Bebek, S. Langer, Lana Botak, Petar Jazbec, V. Ramljak, I. Milas
Introduction: In Croatia, about 3,500 patients are diagnosed with a colorectal carcinoma annually. The National Program for Early Detection of Colon Cancer has been implemented in Croatia since 2007. The program’s primary goal is todetect colon cancer at an early stage of the disease, which should reduce the incidence and mortality from colon cancer. Aim: To determine the interest of the target group in participating in the program, reasons for not responding to the program, and their knowledge about it altogether. Materials and methods: Surveying 50 patients within the program’s target group about their response to and understanding of reasons for screening. Results: Although 84% of the participants know about the program, the response rate was unsatisfactory. Conclusion: Most of the respondents who suffered from a colorectal carcinoma received a call but did not respond due to the absence of symptoms, which correlates with a low level of knowledge on colorectal carcinoma.
{"title":"Lack of information on colorectal cancer in general public might be the reason for low response rates to screening progam","authors":"M. Bebek, S. Langer, Lana Botak, Petar Jazbec, V. Ramljak, I. Milas","doi":"10.20471/lo.2022.50.02-03.11","DOIUrl":"https://doi.org/10.20471/lo.2022.50.02-03.11","url":null,"abstract":"Introduction: In Croatia, about 3,500 patients are diagnosed with a colorectal carcinoma annually. The National Program for Early Detection of Colon Cancer has been implemented in Croatia since 2007. The program’s primary goal is todetect colon cancer at an early stage of the disease, which should reduce the incidence and mortality from colon cancer. Aim: To determine the interest of the target group in participating in the program, reasons for not responding to the program, and their knowledge about it altogether. Materials and methods: Surveying 50 patients within the program’s target group about their response to and understanding of reasons for screening. Results: Although 84% of the participants know about the program, the response rate was unsatisfactory. Conclusion: Most of the respondents who suffered from a colorectal carcinoma received a call but did not respond due to the absence of symptoms, which correlates with a low level of knowledge on colorectal carcinoma.","PeriodicalId":53700,"journal":{"name":"Libri Oncologici","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48782808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-12-22DOI: 10.20471/lo.2022.50.02-03.18
Marija Ban, E. Vrdoljak
Breast cancer cells can express HER2 receptors on their membranes to varying degrees. HER2 signalling pathway is important for tumor growth and metastasis. Patients with HER2-positive disease had worse treatment outcomes until the implementation of trastuzumab started, followed by other anti-HER2 drugs. So far, they have been used exclusively for strong HER2 expression. The development of new drugs, primarily antibody-drug conjugates, has proven their efficacy on tumor cells that have lower levels of the HER2 receptors, today referred to as HER2-low tumors. Since the results of the DESTINY breast04 study showed a prolongation of progression free survival and overall survival in HER2-low pretreated patients, a new perspective opens up in the treatment, as well as in HER2 testing.
{"title":"HER2-low advanced breast cancer treatment","authors":"Marija Ban, E. Vrdoljak","doi":"10.20471/lo.2022.50.02-03.18","DOIUrl":"https://doi.org/10.20471/lo.2022.50.02-03.18","url":null,"abstract":"Breast cancer cells can express HER2 receptors on their membranes to varying degrees. HER2 signalling pathway is important for tumor growth and metastasis. Patients with HER2-positive disease had worse treatment outcomes until the implementation of trastuzumab started, followed by other anti-HER2 drugs. So far, they have been used exclusively for strong HER2 expression. The development of new drugs, primarily antibody-drug conjugates, has proven their efficacy on tumor cells that have lower levels of the HER2 receptors, today referred to as HER2-low tumors. Since the results of the DESTINY breast04 study showed a prolongation of progression free survival and overall survival in HER2-low pretreated patients, a new perspective opens up in the treatment, as well as in HER2 testing.","PeriodicalId":53700,"journal":{"name":"Libri Oncologici","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42131377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-12-22DOI: 10.20471/lo.2022.50.02-03.19
Ana Magličić, P. Podolski, Nera Šarić, M. Soče, M. Baučić, Sanja Vušković, Tena Mlinarić-Koprivanac, Dora Šimović, Petra Đelalija, I. Zrilić, M. Bašić-Koretić
Breast cancer, along with lung cancer and melanoma, is one of the most common origins of central nervous system metastases. Due to improvement of systemic therapy options for primary disease and consequential prolonged survival, treatment of brain metastasis (BM) is presenting an evolving challenge. While new systemic therapy approaches for breast cancer brain metastasis are focusing on overcoming the blood brain and blood tumor barrier, as well as targeted therapies, local therapy remains the primary line of treatment. The decision of which local therapies to use, depends upon the number and volume of BM, their localization, patient’s clinical status, previously used treatments, status of extracranial disease and patient’s prognosis. In cases when an active approach, including surgery and/or radiotherapy, does not bring benefit to the patient’s quality of life or overall survival, best supportive care is recommended.
{"title":"Local treatment of breast cancer brain metastases","authors":"Ana Magličić, P. Podolski, Nera Šarić, M. Soče, M. Baučić, Sanja Vušković, Tena Mlinarić-Koprivanac, Dora Šimović, Petra Đelalija, I. Zrilić, M. Bašić-Koretić","doi":"10.20471/lo.2022.50.02-03.19","DOIUrl":"https://doi.org/10.20471/lo.2022.50.02-03.19","url":null,"abstract":"Breast cancer, along with lung cancer and melanoma, is one of the most common origins of central nervous system metastases. Due to improvement of systemic therapy options for primary disease and consequential prolonged survival, treatment of brain metastasis (BM) is presenting an evolving challenge. While new systemic therapy approaches for breast cancer brain metastasis are focusing on overcoming the blood brain and blood tumor barrier, as well as targeted therapies, local therapy remains the primary line of treatment. The decision of which local therapies to use, depends upon the number and volume of BM, their localization, patient’s clinical status, previously used treatments, status of extracranial disease and patient’s prognosis. In cases when an active approach, including surgery and/or radiotherapy, does not bring benefit to the patient’s quality of life or overall survival, best supportive care is recommended.","PeriodicalId":53700,"journal":{"name":"Libri Oncologici","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47198787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-12-22DOI: 10.20471/lo.2022.50.02-03.17
D. Grebić, P. Valković-Zujić, Iva Pozderac, Domagoj Kustić, Matea Hrboka-Zekić
Introduction: Breast cancer is the most commonly diagnosed malignancy in women and the leading cause of cancer death in women. Tumor size is a critical factor in determining the type and extent of surgical and oncologic treatment. It is accurately determined by imaging modalities such as mammography, ultrasound, and magnetic resonance imaging (MRI), which provide a more reliable determination of tumor size. The aim of our study was to investigate the impact of preoperative breast magnetic resonance imaging on surgical treatment of newly diagnosed breast cancer. Material and Methods: The study retrospectively reviewed the records of 241 participants with newly diagnosed breast cancer who underwent preoperative mammography, breast ultrasound, and MRI between 2016 and 2020 at University Hospital Centre Rijeka. Patients were diagnosed with invasive ductal carcinoma, invasive lobular carcinoma, ductal carcinoma in situ, or a combination of the types. Surgical treatment included one of the following procedures: simple quadrantectomy, quadrantectomy and sentinel lymph node biopsy, quadrantectomy and axillary lymph node dissection, mastectomy and sentinel biopsy, or mastectomy and axillary dissection. Results: Compared with histopathologic tumor size, breast MRI overestimated size in 10% of patients. T stage was underestimated in 5% of patients (p>0.050). In comparison, breast ultrasound overestimated tumor size in 12% and underestimated it in 48% (p<0.001). Similarly, mammography overestimated tumor size in 14% and underestimated it in 62% (p<0.001). Conclusion: In patients with newly diagnosed breast cancer, the use of preoperative breast MRI as an adjunct to mammography and ultrasound for locoregional staging significantly alters subsequent surgical treatment.
{"title":"Resonance imaging on the surgical management of newly diagnosed breast cancer","authors":"D. Grebić, P. Valković-Zujić, Iva Pozderac, Domagoj Kustić, Matea Hrboka-Zekić","doi":"10.20471/lo.2022.50.02-03.17","DOIUrl":"https://doi.org/10.20471/lo.2022.50.02-03.17","url":null,"abstract":"Introduction: Breast cancer is the most commonly diagnosed malignancy in women and the leading cause of cancer death in women. Tumor size is a critical factor in determining the type and extent of surgical and oncologic treatment. It is accurately determined by imaging modalities such as mammography, ultrasound, and magnetic resonance imaging (MRI), which provide a more reliable determination of tumor size. The aim of our study was to investigate the impact of preoperative breast magnetic resonance imaging on surgical treatment of newly diagnosed breast cancer. Material and Methods: The study retrospectively reviewed the records of 241 participants with newly diagnosed breast cancer who underwent preoperative mammography, breast ultrasound, and MRI between 2016 and 2020 at University Hospital Centre Rijeka. Patients were diagnosed with invasive ductal carcinoma, invasive lobular carcinoma, ductal carcinoma in situ, or a combination of the types. Surgical treatment included one of the following procedures: simple quadrantectomy, quadrantectomy and sentinel lymph node biopsy, quadrantectomy and axillary lymph node dissection, mastectomy and sentinel biopsy, or mastectomy and axillary dissection. Results: Compared with histopathologic tumor size, breast MRI overestimated size in 10% of patients. T stage was underestimated in 5% of patients (p>0.050). In comparison, breast ultrasound overestimated tumor size in 12% and underestimated it in 48% (p<0.001). Similarly, mammography overestimated tumor size in 14% and underestimated it in 62% (p<0.001). Conclusion: In patients with newly diagnosed breast cancer, the use of preoperative breast MRI as an adjunct to mammography and ultrasound for locoregional staging significantly alters subsequent surgical treatment.","PeriodicalId":53700,"journal":{"name":"Libri Oncologici","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42543517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-12-22DOI: 10.20471/lo.2022.50.02-03.10
N. Neshev, I. Ignatov, R. Toshkova, Cristos Drossinakis, G. Gluhchev
The aim of the present study was to estimate the feasibility of blood serum hydrogen bonds energy distribution, and information-theoretic characteristics, as diagnostic markers for tumor disease in Graffi tumor bearing hamsters. Golden Syrian hamsters were randomly divided into two groups: a healthy control and an experimental one, challenged with Graffi tumor cells. The distributions of hydrogen bonds energies (-E) in the blood serum samples were investigated with a nonequilibrium process of droplets evaporation and sequential measurements of their wetting angle (Non-equilibrium Energy Spectrum (NES)). The measurements show significantly lower average hydrogen bond energy of the experimental samples than the controls. Shifts in NES toward depletion of (-E) at energy levels 0.0937, 0.1187, 0.1212, 0.1337, and 0.1387 eV, and an additional population at 0.0987, 0.1012, 0.1137, and 0.1237 eV energy levels were observed in the experimental samples compared to the controls. Such a pattern points to the possibility of utilizing the f(E) shifts at these energy levels as diagnostic markers of Graffi tumor in hamsters. Information-theoretic measures of Shannon entropy, Variation of information and Transformational information entropy were used to investigate possible differences between the experimental and control spectrum. Although they differ significantly in definitions, a comparison with the three information-theoretic measures did not reveal a statistically significant difference.
本研究的目的是评估血清氢键能量分布和信息论特征作为格拉菲荷瘤仓鼠肿瘤疾病诊断指标的可行性。金色叙利亚仓鼠被随机分为两组:一组是健康对照组，另一组是受Graffi肿瘤细胞攻击的实验组。通过液滴蒸发的非平衡过程和液滴润湿角(Non-equilibrium Energy Spectrum, NES)的连续测量，研究了血清样品中氢键能(-E)的分布。测量结果表明，实验样品的平均氢键能明显低于对照。在实验样本中，与对照组相比，在能量水平为0.0937、0.1187、0.1212、0.1337和0.1387 eV时，NES向(-E)耗竭的转变，以及在能量水平为0.0987、0.1012、0.1137和0.1237 eV时的额外群体。这种模式指出了利用这些能量水平上的f(E)位移作为仓鼠Graffi肿瘤诊断标志物的可能性。利用Shannon熵、信息变异和转换信息熵的信息理论度量来研究实验谱和控制谱之间可能存在的差异。虽然它们在定义上有很大的不同，但与三种信息理论测量的比较并没有显示出统计学上的显著差异。
{"title":"Hydrogen bonds energy distribution and information-theoretic analysis of blood serum from hamsters with experimental Graffi tumor","authors":"N. Neshev, I. Ignatov, R. Toshkova, Cristos Drossinakis, G. Gluhchev","doi":"10.20471/lo.2022.50.02-03.10","DOIUrl":"https://doi.org/10.20471/lo.2022.50.02-03.10","url":null,"abstract":"The aim of the present study was to estimate the feasibility of blood serum hydrogen bonds energy distribution, and information-theoretic characteristics, as diagnostic markers for tumor disease in Graffi tumor bearing hamsters. Golden Syrian hamsters were randomly divided into two groups: a healthy control and an experimental one, challenged with Graffi tumor cells. The distributions of hydrogen bonds energies (-E) in the blood serum samples were investigated with a nonequilibrium process of droplets evaporation and sequential measurements of their wetting angle (Non-equilibrium Energy Spectrum (NES)). The measurements show significantly lower average hydrogen bond energy of the experimental samples than the controls. Shifts in NES toward depletion of (-E) at energy levels 0.0937, 0.1187, 0.1212, 0.1337, and 0.1387 eV, and an additional population at 0.0987, 0.1012, 0.1137, and 0.1237 eV energy levels were observed in the experimental samples compared to the controls. Such a pattern points to the possibility of utilizing the f(E) shifts at these energy levels as diagnostic markers of Graffi tumor in hamsters. Information-theoretic measures of Shannon entropy, Variation of information and Transformational information entropy were used to investigate possible differences between the experimental and control spectrum. Although they differ significantly in definitions, a comparison with the three information-theoretic measures did not reveal a statistically significant difference.","PeriodicalId":53700,"journal":{"name":"Libri Oncologici","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41478495","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-12-22DOI: 10.20471/lo.2022.50.02-03.21
Sandra Radović-Radovčić, Egon Kruezi, Jasna Martinčević, Lana Postružin-Gršić, Kristina Čimić
Endometrial cancer is the sixth most common cancer in women worldwide and fourth in Europe. Global estimates show rising incidence in both developed and developing countries. Standard surgical treatment leads to permanent loss of fertility. With current trends of reproductive-age women delaying childbearing, rising endometrial carcinoma incidence rates and a growing epidemic of obesity, research on conservative treatment remains a priority. Fertility-sparing treatment involves the use of oral progestins and levonorgestrel-releasing intrauterine devices, both shown to be beneficial and safe in early-stage endometrial carcinoma. We present a case of a 40-year-old female with endometrial adenocarcinoma grade 1 diagnosed during infertility workup. After one year of levonorgestrel-releasing intrauterine devices and almost three years after initial diagnosis was made, pregnancy was achieved. Term elective C-section delivery was done and a healthy infant was born. Today, a 46-yearold female, with six years of disease-free survival, still opts for conservative treatment. Aim of this paper is to show how conservative management with steady follow up in highly motivated individuals could be a reliable option for females of reproductive age with endometrial malignancies. Concept of fertility-sparing treatment should give hope to patients with malignant disease and unfulfilled reproductive goals.
{"title":"Successful pregnancy in women with endometrial carcinoma","authors":"Sandra Radović-Radovčić, Egon Kruezi, Jasna Martinčević, Lana Postružin-Gršić, Kristina Čimić","doi":"10.20471/lo.2022.50.02-03.21","DOIUrl":"https://doi.org/10.20471/lo.2022.50.02-03.21","url":null,"abstract":"Endometrial cancer is the sixth most common cancer in women worldwide and fourth in Europe. Global estimates show rising incidence in both developed and developing countries. Standard surgical treatment leads to permanent loss of fertility. With current trends of reproductive-age women delaying childbearing, rising endometrial carcinoma incidence rates and a growing epidemic of obesity, research on conservative treatment remains a priority. Fertility-sparing treatment involves the use of oral progestins and levonorgestrel-releasing intrauterine devices, both shown to be beneficial and safe in early-stage endometrial carcinoma. We present a case of a 40-year-old female with endometrial adenocarcinoma grade 1 diagnosed during infertility workup. After one year of levonorgestrel-releasing intrauterine devices and almost three years after initial diagnosis was made, pregnancy was achieved. Term elective C-section delivery was done and a healthy infant was born. Today, a 46-yearold female, with six years of disease-free survival, still opts for conservative treatment. Aim of this paper is to show how conservative management with steady follow up in highly motivated individuals could be a reliable option for females of reproductive age with endometrial malignancies. Concept of fertility-sparing treatment should give hope to patients with malignant disease and unfulfilled reproductive goals.","PeriodicalId":53700,"journal":{"name":"Libri Oncologici","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42859238","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：